Literature DB >> 17502363

Gelatinase expression and proteolytic activity in giant-cell arteritis.

Marta Segarra1, Ana García-Martínez, Montse Sánchez, José Hernández-Rodríguez, Ester Lozano, Josep M Grau, Maria C Cid.   

Abstract

OBJECTIVES: Gelatinases (MMP2 and MMP9) are expressed in giant-cell arteritis (GCA) and are thought to play a role in vessel disruption. However, their activation status and enzymatic activity have not been evaluated. Our aim was to investigate the distribution and proteolytic activity of gelatinases in GCA lesions at different stages.
METHODS: Expression of MMP2, MMP9, MMP2-activator MMP14 and their natural inhibitors TIMP1 and TIMP2 was determined by real-time PCR and immunohistochemistry in temporal artery sections from 46 patients and 12 controls. MMP activation status and enzymatic activity were assessed by gelatin and film in situ zymography.
RESULTS: Vascular smooth muscle cells from normal specimens constitutively expressed pro-MMP2 and its inhibitor TIMP2 with no resulting proteolytic activity. In GCA MMP2, MMP9 and MMP14 were strongly expressed in their active form by infiltrating leucocytes. Inflamed arteries also expressed TIMP1 and TIMP2. However, the MMP9/TIMP1 and MMP2/TIMP2 ratios were higher in patients compared with controls, indicating an increased proteolytic balance in GCA which was confirmed by in situ zymography. Maximal gelatinase expression and activity occurred at the granulomatous areas surrounding the internal elastic lamina (IEL). Myointimal cells also expressed MMPs and exhibited proteolytic activity, suggesting a role for gelatinases in vascular remodelling and repair.
CONCLUSIONS: GCA lesions show intense expression of gelatinases. Activators and inhibitors are regulated to yield enhanced gelatinase activation and proteolytic activity. Distribution of expression and proteolytic activity suggests that gelatinases have a major role not only in the progression of inflammatory infiltrates and vessel destruction but also in vessel repair.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17502363      PMCID: PMC2111616          DOI: 10.1136/ard.2006.068148

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  34 in total

1.  A critical role for elastin signaling in vascular morphogenesis and disease.

Authors:  Satyajit K Karnik; Benjamin S Brooke; Antonio Bayes-Genis; Lise Sorensen; Joshua D Wythe; Robert S Schwartz; Mark T Keating; Dean Y Li
Journal:  Development       Date:  2003-01       Impact factor: 6.868

Review 2.  MMPs and TIMPs--an historical perspective.

Authors:  J Frederick Woessner
Journal:  Mol Biotechnol       Date:  2002-09       Impact factor: 2.695

3.  Signal transducers and activators of transcription-3 up-regulates tissue inhibitor of metalloproteinase-1 expression and decreases invasiveness of breast cancer.

Authors:  Jennifer Dien; Hesham M Amin; Neil Chiu; Winson Wong; Christine Frantz; Brian Chiu; John R Mackey; Raymond Lai
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

4.  Cell adhesion molecules in the development of inflammatory infiltrates in giant cell arteritis: inflammation-induced angiogenesis as the preferential site of leukocyte-endothelial cell interactions.

Authors:  M C Cid; M Cebrián; C Font; B Coll-Vinent; J Hernández-Rodríguez; J Esparza; A Urbano-Márquez; J M Grau
Journal:  Arthritis Rheum       Date:  2000-01

5.  Hydrocortisone suppresses intranuclear activator-protein-1 (AP-1) binding activity in mononuclear cells and plasma matrix metalloproteinase 2 and 9 (MMP-2 and MMP-9).

Authors:  A Aljada; H Ghanim; P Mohanty; D Hofmeyer; D Tripathy; P Dandona
Journal:  J Clin Endocrinol Metab       Date:  2001-12       Impact factor: 5.958

6.  Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms.

Authors:  G Matthew Longo; Wanfen Xiong; Timothy C Greiner; Yong Zhao; Nicola Fiotti; B Timothy Baxter
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

Review 7.  Strategies for MMP inhibition in cancer: innovations for the post-trial era.

Authors:  Christopher Mark Overall; Carlos López-Otín
Journal:  Nat Rev Cancer       Date:  2002-09       Impact factor: 60.716

8.  Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism.

Authors:  José Hernández-Rodríguez; Marta Segarra; Carme Vilardell; Montse Sánchez; Ana García-Martínez; María-José Esteban; Josep M Grau; Alvaro Urbano-Márquez; Dolors Colomer; Hynda K Kleinman; Maria C Cid
Journal:  Circulation       Date:  2003-05-12       Impact factor: 29.690

9.  Tissue and serum angiogenic activity is associated with low prevalence of ischemic complications in patients with giant-cell arteritis.

Authors:  Maria C Cid; José Hernández-Rodríguez; María-José Esteban; Mireia Cebrián; Yong Song Gho; Carme Font; Alvaro Urbano-Márquez; Josep M Grau; Hynda K Kleinman
Journal:  Circulation       Date:  2002-09-24       Impact factor: 29.690

10.  The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis.

Authors:  Takeshi Itoh; Hidetoshi Matsuda; Masatoshi Tanioka; Kenji Kuwabara; Shigeyoshi Itohara; Ryuji Suzuki
Journal:  J Immunol       Date:  2002-09-01       Impact factor: 5.422

View more
  18 in total

Review 1.  Translational mini-review series on immunology of vascular disease: mechanisms of vascular inflammation and remodelling in systemic vasculitis.

Authors:  N Maugeri; P Rovere-Querini; M Baldini; M G Sabbadini; A A Manfredi
Journal:  Clin Exp Immunol       Date:  2009-03-20       Impact factor: 4.330

2.  MMP-12, a novel matrix metalloproteinase associated with giant cell arteritis.

Authors:  Alicia Rodríguez-Pla; Francisco Martínez-Murillo; Peter J Savino; Ralph C Eagle; Philip Seo; Mark J Soloski
Journal:  Rheumatology (Oxford)       Date:  2009-09-06       Impact factor: 7.580

3.  Evaluation of Potential Serum Biomarkers of Disease Activity in Diverse Forms of Vasculitis.

Authors:  Alicia Rodriguez-Pla; Roscoe L Warner; David Cuthbertson; Simon Carette; Nader A Khalidi; Curry L Koening; Carol A Langford; Carol A McAlear; Larry W Moreland; Christian Pagnoux; Philip Seo; Ulrich Specks; Antoine G Sreih; Steven R Ytterberg; Kent J Johnson; Peter A Merkel; Paul A Monach
Journal:  J Rheumatol       Date:  2019-09-01       Impact factor: 4.666

Review 4.  Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities.

Authors:  Christian Dejaco; Elisabeth Brouwer; Justin C Mason; Frank Buttgereit; Eric L Matteson; Bhaskar Dasgupta
Journal:  Nat Rev Rheumatol       Date:  2017-09-14       Impact factor: 20.543

Review 5.  Clinical features of polymyalgia rheumatica and giant cell arteritis.

Authors:  Carlo Salvarani; Nicolò Pipitone; Annibale Versari; Gene G Hunder
Journal:  Nat Rev Rheumatol       Date:  2012-07-24       Impact factor: 20.543

Review 6.  Large-vessel vasculitis.

Authors:  Dan Pugh; Maira Karabayas; Neil Basu; Maria C Cid; Ruchika Goel; Carl S Goodyear; Peter C Grayson; Stephen P McAdoo; Justin C Mason; Catherine Owen; Cornelia M Weyand; Taryn Youngstein; Neeraj Dhaun
Journal:  Nat Rev Dis Primers       Date:  2022-01-06       Impact factor: 65.038

Review 7.  Giant Cell Arteritis: Beyond Corticosteroids.

Authors:  Lauren Steel; Asad Khan; Bhaskar Dasgupta
Journal:  Drugs Aging       Date:  2015-08       Impact factor: 3.923

8.  Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis--a prospective longitudinal study.

Authors:  Sudha Visvanathan; Mahboob U Rahman; Gary S Hoffman; Stephen Xu; Ana García-Martínez; Marta Segarra; Ester Lozano; Georgina Espígol-Frigolé; José Hernández-Rodríguez; Maria C Cid
Journal:  Rheumatology (Oxford)       Date:  2011-08-25       Impact factor: 7.580

9.  Effect of glucocorticoid treatment on computed tomography angiography detected large-vessel inflammation in giant-cell arteritis. A prospective, longitudinal study.

Authors:  Sergio Prieto-González; Ana García-Martínez; Itziar Tavera-Bahillo; José Hernández-Rodríguez; José Gutiérrez-Chacoff; Marco A Alba; Giuseppe Murgia; Georgina Espígol-Frigolé; Marcelo Sánchez; Pedro Arguis; Maria C Cid
Journal:  Medicine (Baltimore)       Date:  2015-02       Impact factor: 1.889

10.  HSPC117 is regulated by epigenetic modification and is involved in the migration of JEG-3 cells.

Authors:  Hong Ma; Mei-Yu Qi; Xu Zhang; Yue-Ling Zhang; Liang Wang; Zhong-Qiu Li; Bo Fu; Wen-Tao Wang; Di Liu
Journal:  Int J Mol Sci       Date:  2014-06-17       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.